NVP is advancing a new generation of targeted nanosphere (TNS) based products incorporating our core and highly optimized HPLN (Hybrid Polymerized Liposomal Nanoparticle) technology. These targeted nanospheres may provide a vast improvement in flexibility and choice for patients restricted by current treatment options including antibody, immunotherapy and ADC based products. Both by repositioning existing therapies such as chemotherapeutics and by optimising the delivery of emerging candidates including small molecules and nucleic acid based.
Our current main candidate focus is in oncology, initially pediatric focused, with NV103, but it is already clear that once validated the technology can be clearly applied to broader oncology challenges, as well as areas such as surgery/devices where we have a pipeline candidate, imaging, vaccines, and other non-oncological sectors as opportunities present. We have other candidates such as NV101, NV102 and NV201 plus rapidly progressing pilot programs in nucleic acid delivery and in trans-BBB (blood brain barrier) related therapy for brain located cancers.